These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 20847692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
    Clercq ED.
    Biochem Pharmacol; 2012 Mar 01; 83(5):567-73. PubMed ID: 22067069
    [Abstract] [Full Text] [Related]

  • 3. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR, Morrow JS.
    Clin Infect Dis; 2008 Oct 01; 47(7):984-5. PubMed ID: 18778234
    [No Abstract] [Full Text] [Related]

  • 4. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
    De Clercq E.
    Expert Opin Pharmacother; 2009 Dec 01; 10(17):2935-7. PubMed ID: 19929712
    [Abstract] [Full Text] [Related]

  • 5. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr 28; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Lapadula G, Costarelli S, Quiros-Roldan E, Calabresi A, Izzo I, Carosi G, Torti C.
    Clin Infect Dis; 2008 Apr 01; 46(7):1127-9. PubMed ID: 18444839
    [No Abstract] [Full Text] [Related]

  • 8. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
    Hsu R, Lanier ER, Rouse EG, Oie KL, Pappa KA, Ross LL.
    Antivir Ther; 2008 Apr 01; 13(5):735-7. PubMed ID: 18771059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
    Kersh EN, Luo W, Adams DR, Mitchell J, Garcia-Lerma JG, Heneine W, Folks TM, Butera S, Otten RA.
    AIDS Res Hum Retroviruses; 2008 Apr 01; 24(4):543-6. PubMed ID: 18370590
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [HIV preexposure prophylaxis].
    Olczak A, Grabczewska E.
    Przegl Epidemiol; 2012 Apr 01; 66(1):79-82. PubMed ID: 22708303
    [Abstract] [Full Text] [Related]

  • 14. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.
    AIDS; 2009 Apr 27; 23(7):825-33. PubMed ID: 19307941
    [Abstract] [Full Text] [Related]

  • 15. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.
    J Antimicrob Chemother; 2005 Dec 27; 56(6):1087-93. PubMed ID: 16269552
    [Abstract] [Full Text] [Related]

  • 16. Considerations regarding antiretroviral chemoprophylaxis in MSM.
    Poynten IM, Zablotska I, Grulich AE.
    Curr Opin HIV AIDS; 2012 Nov 27; 7(6):549-56. PubMed ID: 22918448
    [Abstract] [Full Text] [Related]

  • 17. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
    Cong ME, Youngpairoj AS, Aung W, Sharma S, Mitchell J, Dobard C, Heneine W, Garcia-Lerma JG.
    Virology; 2011 Apr 10; 412(2):435-40. PubMed ID: 21334708
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE, Chan DJ, Maruszak H, Jeganathan S.
    Int J STD AIDS; 2011 Apr 10; 22(4):228-30. PubMed ID: 21515757
    [Abstract] [Full Text] [Related]

  • 19. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P.
    Expert Rev Anti Infect Ther; 2009 Sep 10; 7(7):801-5. PubMed ID: 19735222
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.